4509 POSTER Sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC): updated efficacy and safety results and further analysis of prognostic factors
Explore this paper's citation graph
Summary
Investigation of the activity of cis-UCA and other anti-cancer drugs against human urinary bladder cancer cell lines in vitro found decreased viability and proliferation activity was always accompanied by distinct morphological changes observed in light microscopy.
- Type
- article
- Published
- 2007-09-01
- Cited by
- 15
- References
- 0
- OpenAlex
- https://openalex.org/W1972690635
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:206128479
Keywords
Sunitinib, Medicine, Renal cell carcinoma, Oncology, Internal medicine
References
No references recorded for this paper.
Cited by
- Systemtherapie des metastasierten Nierenzellkarzinoms
- Pazopanib for the First-Line Treatment of Patients with Advanced and/or Metastatic Renal Cell Carcinoma
- Targeted therapy for advanced renal cell carcinoma.
- Sunitinib for the treatment of metastatic renal cell carcinoma.
- Sunitinib in Advanced Renal Cell Carcinoma: Clinical Evidence
- Tyrosine Kinase Inhibitors in Clinical Practice: Patient Selection
- Prognostic Factors: Does It Really Matter if New Drugs for Targeted Therapy Will Be Used?
- Molecular basis for sunitinib efficacy and future clinical development
- Optimal management of metastatic renal cell carcinoma: an algorithm for treatment
- Defining risk status in the first-line treatment of metastatic renal cell carcinoma
- Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness
- Prospective assessment of systemic therapy followed by surgical removal of metastases in selected patients with renal cell carcinoma
- Improving outcomes in patients with advanced renal cell carcinoma
- Targeted therapy for metastatic renal cell carcinoma.
Related papers
- Ischaemic stroke in a patient on sunitinib
- Improvement of Psoriasis During Sunitinib Therapy for Renal Cell Carcinoma
- Sunitinib as a molecular targeting agent in renal cell carcinoma
- PCN135 IMPROVEMENT IN QUALITY OF LIFE OUTCOMES IN INTERFERONALPHA TREATED PATIENTS COMPARED TO SUNITINIB IN ADVANCE OR METASTATIC RENAL CELL CARCINOMA
- 11C-Acetate PET for Early Prediction of Sunitinib Response in Metastatic Renal Cell Carcinoma
- Very Late Recurrence of Renal Cell Carcinoma Experiencing Long-term Response to Sunitinib: A Case Report
- Sunitinib Associated Per Rectal Bleeding in a Patient with Metastatic Renal Cell Carcinoma-A Case Report
- Sunitinib in renal-cell carcinoma: expanded indications.
- Targeted therapies: Sunitinib versus interferon-α in metastatic RCC